AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27868341 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (SC)
Number of subjects: 53
Study 25963675 — intervention group
Group type: EXPERIMENTAL
Intervention: SALT (Supraglottic Airway Laryngopharyngeal Tube)
Number of subjects: 210
Study 25963675 — intervention group
Group type: COMPARATOR
Intervention: ILMA
Number of subjects: 210
Study 25963675 — intervention group
Group type: COMPARATOR
Intervention: Cobra PLA
Number of subjects: 210
Study 25963675 — intervention group
Group type: COMPARATOR
Intervention: Air‐Q
Number of subjects: 210
Study 23451885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 120 mg twice daily
Number of subjects: 14
Study 23451885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21766075 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida species in RT cultures
Number of subjects: 274
Study 21766075 — intervention group
Group type: COMPARATOR
Intervention: No Candida species in RT cultures
Number of subjects: 274
Study 18854724 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER < or =225 mg/day
Number of subjects: 1096
Study 18854724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1096
Study 16614416 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF in capsule form (4.45 mg/kg body weight)
Number of subjects: 11
Study 16614416 — intervention group
Group type: EXPERIMENTAL
Intervention: RCOF (4.45 mg/kg body weight caffeine)
Number of subjects: 11
Study 16614416 — intervention group
Group type: EXPERIMENTAL
Intervention: DECAF (equal in volume to the RCOF trial)
Number of subjects: 11
Study 16614416 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (placebo, PL)
Number of subjects: 11
Study 16450533 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral azithromycin (20 mg/kg)
Number of subjects: 772
Study 16450533 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without trachoma
Number of subjects: 772
Study 10720508 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp160
Number of subjects: 608
Study 10720508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 9265807 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received two 50-minute sessions embedding suggestions from Gurdjieff.
Number of subjects: 24
Study 9265807 — intervention group
Group type: COMPARATOR
Intervention: Control group read material on achieving increased control.
Number of subjects: 24
Study 7688381 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg orally) 12 hours before surgical interruption
Number of subjects: 60
Study 7688381 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg orally) 24 hours before surgical interruption
Number of subjects: 60
Study 7688381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) 24 hours before vacuum aspiration
Number of subjects: 60
Study 3091164 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25‐50 mg twice a day)
Number of subjects: 16
Study 3091164 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12 weeks treatment)
Number of subjects: 16
Study 3091164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31790073 — intervention group
Group type: EXPERIMENTAL
Intervention: Casino shifts (2000 to 0400 hours and 0400 to 1200 hours)
Number of subjects: 124
Study 31790073 — intervention group
Group type: COMPARATOR
Intervention: Standard overnight shifts (midnight to 0800 hours)
Number of subjects: 124
Study 31790073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood faces rating scale
Number of subjects: 124
Study 31790073 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-item postblock survey based on WHO domains for quality of life
Number of subjects: 124
Study 28887843 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) ingestion
Number of subjects: 0
Study 28887843 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in HDL-related variables after VOO ingestion
Number of subjects: 0
Study 26266427 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.77%
Number of subjects: 345
Study 26266427 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 345
Study 24646101 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog injections plus daily topical testosterone gel
Number of subjects: 100
Study 24646101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22568998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 22568998 — intervention group
Group type: COMPARATOR
Intervention: Interferon-α (IFN-α)
Number of subjects: 0
Study 18636265 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravitreal injection of 1.25 mg bevacizumab
Number of subjects: 32
Study 18636265 — intervention group
Group type: EXPERIMENTAL
Intervention: Second injection of bevacizumab after a mean of 19+/‐8 weeks
Number of subjects: 32
Study 18636265 — intervention group
Group type: EXPERIMENTAL
Intervention: Second injection of bevacizumab
Number of subjects: 32
Study 17336650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild treatment (mild ovarian stimulation with GnRH antagonist co-treatment and single embryo transfer)
Number of subjects: 404
Study 17336650 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (stimulation with GnRH agonist long-protocol and transfer of two embryos)
Number of subjects: 404
Study 17336650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild treatment
Number of subjects: 404
Study 17336650 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 404
Study 12691137 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 0
Study 12691137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine-kinase inhibitor STI 571
Number of subjects: 0
Study 10819855 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 531
Study 10819855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study 8623127 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB-irradiated platelet concentrates (PCs)
Number of subjects: 50
Study 8623127 — intervention group
Group type: COMPARATOR
Intervention: Control, nonirradiated platelet concentrates (PCs)
Number of subjects: 50
Study 1616322 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 26
Study 1616322 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-deazaaminopterin
Number of subjects: 26
Study 1616322 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 6696358 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 6696358 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil zinc levels
Number of subjects: 0
Study 6696358 — intervention group
Group type: COMPARATOR
Intervention: Zinc levels in plasma or erythrocytes
Number of subjects: 0
Study 3516096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolazamide (sulfonylurea)
Number of subjects: 11
Study 29164312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine in combination with levodopa
Number of subjects: 0
Study 29164312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29164312 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0
Study 27459163 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (voucher for testing)
Number of subjects: 202
Study 27459163 — intervention group
Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 202
Study 25290792 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary DES
Number of subjects: 27
Study 25290792 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 27
Study 23035006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current electro-massage
Number of subjects: 62
Study 23035006 — intervention group
Group type: COMPARATOR
Intervention: Superficial lower back massage
Number of subjects: 62
Study 20368905 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (12 to 24 mg)
Number of subjects: 0
Study 20368905 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 0
Study 19109853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computerized modules
Number of subjects: 102
Study 19109853 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing material)
Number of subjects: 102
Study 16633107 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (300 microg twice per day) with diuretics (furosemide and spironolactone)
Number of subjects: 20
Study 16633107 — intervention group
Group type: COMPARATOR
Intervention: Octreotide (300 microg twice per day) alone
Number of subjects: 20
Study 16633107 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (furosemide and spironolactone) alone
Number of subjects: 20
Study 16633107 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (furosemide and spironolactone) discontinued for 7 days
Number of subjects: 20
Study 14530477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy logic-based automatic quantitative analysis software for myocardial SPECT
Number of subjects: 343
Study 10902750 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 15
Study 10902750 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 15
Study 10902750 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects with A77 1726
Number of subjects: 15
Study 8936710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotically-induced vasodilation (hypnosis with biofeedback and autogenics)
Number of subjects: 30
Study 8936710 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 30
Study 1405984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, given four times daily for 10 days as a swish and swallow
Number of subjects: 34
Study 1405984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 34
Study 4078027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indoprofen 200 mg
Number of subjects: 0
Study 4078027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indoprofen 400 mg
Number of subjects: 0
Study 4078027 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pentazocine 15 mg
Number of subjects: 0
Study 4078027 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pentazocine 30 mg
Number of subjects: 0
Study 4078027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of pain relief
Number of subjects: 0
Study 29368116 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic Barthel Index (BI) assessment
Number of subjects: 120
Study 29368116 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face assessment of Barthel Index (BI)
Number of subjects: 120
Study 26568636 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT) measurements
Number of subjects: 29
Study 23866920 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT plus usual care
Number of subjects: 73
Study 23866920 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 73
Study 22951521 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker (ARB)
Number of subjects: 60
Study 22951521 — intervention group
Group type: COMPARATOR
Intervention: Non-dihydropyridine calcium channel blocker (CCB)
Number of subjects: 60
Study 22951521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ARB and CCB
Number of subjects: 60
Study 20149946 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional instruction
Number of subjects: 90
Study 20149946 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based instruction
Number of subjects: 90
Study 20149946 — intervention group
Group type: COMPARATOR
Intervention: Web-based instruction
Number of subjects: 90
Study 18677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellumed (high viscosity)
Number of subjects: 12
Study 18677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresh Contacts (low viscosity)
Number of subjects: 12
Study 18677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic protection (1 week prophylactic use of the solution)
Number of subjects: 12
Study 18677237 — intervention group
Group type: COMPARATOR
Intervention: Unprotected (no test solution used)
Number of subjects: 12
Study 18677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate protection (test solution instilled just before application of TST)
Number of subjects: 12
Study 18677237 — intervention group
Group type: EXPERIMENTAL
Intervention: Relief (test solution instilled just after application of TST)
Number of subjects: 12
Study 15671558 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus HDC
Number of subjects: 19
Study 15671558 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 19
Study 15671558 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC + IL-2
Number of subjects: 19
Study 12731666 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori in 29 infected ITP patients (93% success rate, 27 patients)
Number of subjects: 61
Study 12731666 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori in 29 infected ITP patients
Number of subjects: 61
Study 12731666 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved a major response
Number of subjects: 61
Study 10390264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefixime for 14 days (double dose on day 1)
Number of subjects: 306
Study 10390264 — intervention group
Group type: COMPARATOR
Intervention: Initial intravenous cefotaxime for 3 days followed by oral cefixime for 11 days
Number of subjects: 306
Study 8814691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pamidronate, 300 mg/day (n = 65)
Number of subjects: 124
Study 8814691 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 124
Study 8814691 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life measurements
Number of subjects: 124
Study 2004793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (20 mg)
Number of subjects: 49
Study 2004793 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 ml dextrose)
Number of subjects: 49
Study 6366125 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF 12 cycles
Number of subjects: 0
Study 6366125 — intervention group
Group type: COMPARATOR
Intervention: CMF 6 cycles
Number of subjects: 0
Study 31233996 — intervention group
Group type: EXPERIMENTAL
Intervention: Event Recorder Feedback group
Number of subjects: 150
Study 31233996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (Event Recorder Feedback and parent communication)
Number of subjects: 150
Study 31233996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 28065624 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicondylar knee arthroplasty (UKA)
Number of subjects: 80
Study 28065624 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 80
Study 26190091 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (1440El.U; Havrix; GSK Vaccines) administered according to a 0-6 month schedule.
Number of subjects: 121
Study 26190091 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (1440El.U; Havrix; GSK Vaccines) administered according to a 0-12 month schedule.
Number of subjects: 121
Study 26190091 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV booster administration (1440El.U) after loss of circulating anti-HAV antibodies.
Number of subjects: 121
Study 26190091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical modelling for long-term persistence predictions.
Number of subjects: 121
Study 23422357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake (high quintile >371 mg/day)
Number of subjects: 2475
Study 23422357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption
Number of subjects: 2475
Study 23422357 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake (interaction with vitamin B supplementation)
Number of subjects: 2475
Study 21703023 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician reminders to reconsider aspirin
Number of subjects: 0
Study 21703023 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician and patient messages to reconsider aspirin
Number of subjects: 0
Study 21703023 — intervention group
Group type: COMPARATOR
Intervention: Academic detailing (all practices)
Number of subjects: 0
Study 19335932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) plus Treatment as Usual (TAU)
Number of subjects: 77
Study 19335932 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 77
Study 19681253 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide whitening strips
Number of subjects: 30
Study 19681253 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips
Number of subjects: 30
Study 15498043 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplement of vitamins (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Number of subjects: 117
Study 15498043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 11280825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy (FLEC protocol), median of 3.5 cycles
Number of subjects: 135
Study 11280825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 11280825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy (FLEC protocol)
Number of subjects: 135
Study 9207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetic patients
Number of subjects: 41921
Study 9207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-treated diabetic patients
Number of subjects: 41921
Study 9207639 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 41921
Study 9207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients receiving accelerated t-PA
Number of subjects: 41921
Study 9207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 41921
Study 9207639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing coronary artery bypass graft surgery
Number of subjects: 41921
Study 9207639 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients undergoing coronary artery bypass graft surgery
Number of subjects: 41921
Study 8168798 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment in jail
Number of subjects: 231
Study 8168798 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 231
Study 2889457 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 361 A (10 mg)
Number of subjects: 80
Study 2889457 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 mg)
Number of subjects: 80
Study 2889457 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 80
Study 2889457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29297265 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural beats stimulation
Number of subjects: 0
Study 29297265 — intervention group
Group type: COMPARATOR
Intervention: Control stimulation
Number of subjects: 0
Study 27106794 — intervention group
Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 65
Study 27106794 — intervention group
Group type: COMPARATOR
Intervention: Berne modification
Number of subjects: 65
Study 25957748 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dronabinol (Marinol®)
Number of subjects: 24
Study 25957748 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dronabinol (Marinol®)
Number of subjects: 24
Study 25957748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25957748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg and 20 mg)
Number of subjects: 24
Study 23999456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1615
Study 23999456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1615
Study 21327759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administration in abstinent smokers
Number of subjects: 109
Study 21327759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration in abstinent smokers
Number of subjects: 109
Study 21327759 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration in abstinent smokers
Number of subjects: 109
Study 19290702 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 84
Study 19290702 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized intervention
Number of subjects: 84
Study 19290702 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 84
Study 17728959 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 2734
Study 17728959 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed radiography mammography (CRM)
Number of subjects: 2734
Study 17728959 — intervention group
Group type: COMPARATOR
Intervention: Screen-film mammography (SFM)
Number of subjects: 2734
Study 15176654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg formulation 1
Number of subjects: 23
Study 15176654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg formulation 2
Number of subjects: 23
Study 15176654 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg formulation 1 and 2
Number of subjects: 23
Study 11205494 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Helicobacter pylori infection and daily dietary supplementation with antioxidant micronutrients
Number of subjects: 863
Study 11205494 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline KRAS mutations
Number of subjects: 863